Most Clicked SNMMI SmartBrief Stories

1. SPECT shows promise in distinguishing TBI, PTSD

SNMMI SmartBrief | May 05, 2015

A recent study found SPECT imaging could help differentiate traumatic brain injury from post-traumatic stress disorder. Other types of imaging have not been able to do so. With the ability to assess brain activity and blood flow, SPECT showed 94% accuracy in differentiating the conditions. (05/04)

2. Patients scheduled for imaging may have unanswered questions, study finds

SNMMI SmartBrief | May 01, 2015

A study reported in a radiology journal found only around 46% of 176 patients who were scheduled for medical imaging knew whether radiation was involved in the test, and one in five had unanswered questions about the scan they were about to undergo. Patients tended to have a better understanding of CT scans than nuclear medicine scans, and more than half indicated interest in talking with a radiologist before the test. Reuters (04/30)

3. Nuclear medicine imaging market for SPECT, PET poised for growth, report says

SNMMI SmartBrief | May 04, 2015

An RnR Market Research report predicts the global nuclear medicine imaging market for SPECT and PET devices will hit $2.2 billion by 2020. The growth opportunities will be led by China and Japan, whose market shares are expected to increase by 100% and 75%, respectively. Steady sales are anticipated for the U.S. market at around $1.15 billion through 2020. (free registration) (05/01)

4. Navidea shifts resources away from NAV5001

SNMMI SmartBrief | May 04, 2015

Navidea Biopharmaceuticals has ended its sublicensing deal with Alseres Pharmaceuticals governing the experimental Parkinson's disease imaging agent NAV5001 and is transferring related assets to the company. The move is part of Navidea's plan to divest its non-core neuroimaging assets and cut its research and development costs, focusing instead on cancer care, including its Lymphoseek oncologic imaging agent. Pharmaceutical Business Review Online (04/29)

5. Study examines FDG PET/CT's use in subset of breast cancer patients

SNMMI SmartBrief | Apr 29, 2015

A study presented at the recent meeting of the American Roentgen Ray Society showed that 18F-FDG PET/CT may not be an effective systemic staging tool for people newly diagnosed with stage III breast cancer. The approach failed to detect unsuspected local extraaxillary nodes in all cases. Diagnostic Imaging (04/24)

6. Study: PET with lapatinib zeroes in on brain metastases

SNMMI SmartBrief | Apr 30, 2015

A study in the European Journal of Nuclear Medicine and Molecular Imaging used PET to show radiolabeled lapatinib was able to access brain metastases, with uptake in lesions but not healthy tissue in people with human epidermal growth factor receptor-2-positive breast cancer. 7th Space Interactive (04/30)

7. Study: Women recover from concussion more slowly

SNMMI SmartBrief | Apr 29, 2015

A Taiwanese study found that men's brains may recover more quickly from concussions than women's. Researchers performed functional MRI a month after patients experienced mild traumatic brain injury and saw that the part of the brain that governs short-term memory was more active in men than women. A second scan six weeks later showed brain activity in men had returned to normal, but activity in women had not. Experts said women may need longer physical and mental rest after mild brain trauma. HealthDay News (04/28)

8. Leapfrog releases updated safety scores of U.S. hospitals

SNMMI SmartBrief | Apr 30, 2015

The Leapfrog Group has released the new Hospital Safety Score for more than 2,500 U.S. hospitals. The scores are based on several patient safety and care quality metrics, including infection rates and use of computerized prescribing systems. Maine had the highest percentage of hospitals with an A rating, while no hospitals in Arkansas, North Dakota or Washington, D.C., earned an A. Healthcare IT News (04/29)

9. Molecular imaging among the most key advances in neurocare, health system says

SNMMI SmartBrief | Apr 30, 2015

Partners HealthCare sees promise in the future of neurocare with emerging technologies leading the way. Stem cell treatments for Parkinson's and Alzheimer's disease, use of implantable wireless brain devices and molecular imaging for targeted treatment all promise to continue to advance brain care, the organization said. (04/29)

10. Now available via video: 3rd Theranostics World Congress on Ga-68 and PRRT

SNMMI SmartBrief | May 01, 2015

The 3rd Theranostics World Congress (3TWC) took place on the campus of Johns Hopkins University on March 12-14. Co-sponsored by SNMMI and Johns Hopkins Medicine, the congress covered translational research and current state-of-the-art molecular imaging using 68-Ga PET radiopharmaceuticals and radionuclide therapy. Now every lecture from the Congress is available free via video. Blank (04/29)

Sign up for SNMMI SmartBrief

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more